Positioning biologic therapy for Crohn's disease and ulcerative colitis

Current Gastroenterology Reports

Volumn 9, Issue 6, 2007, Pages 521-527

  Velayos, Fernando S ^a   Sandborn, William J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NATALIZUMAB; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFECTION; LIVER CANCER; LYMPHOMA; MAINTENANCE THERAPY; MONOTHERAPY; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SPLEEN CANCER; STEROID THERAPY; T CELL LYMPHOMA; TREATMENT PLANNING; TUBERCULOSIS; ULCERATIVE COLITIS; BIOLOGICAL THERAPY; DISEASE MANAGEMENT; DRUG ANTAGONISM; INTESTINE MUCOSA; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; WOUND HEALING;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CROHN DISEASE; DISEASE MANAGEMENT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; INTESTINAL MUCOSA; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 44249120374     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-007-0069-1     Document Type: Review

References (50)

1. Louis E, Collard A, Oger AF, et al.: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777-782.
2. Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993, 105:1716-1723.
3. Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
4. Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
5. Sutherland L, Roth D, Beck P, et al.: Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000, (2):CD000543.
6. Akobeng AK, Gardener E: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2005, (1):CD003715.
7. Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836-841.
8. Sandborn WJ, Lofberg R, Feagan BG, et al.: Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005, 100:1780-1787.
9. Summers RW, Switz DM, Sessions JT, Jr, et al.: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77:847-869.
10. Lennard-Jones JE, Misiewicz JJ, Connell AM, et al.: Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965, 1:188-189.
11. Sandborn W, Sutherland L, Pearson D, et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000, (2):CD000545.
12. Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332:292-297.
13. Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
14. Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 2000, 342:1627-1632.
15. Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, (1):CD000478.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
18. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
19. Sandborn W, Colombel JF, Panes J, et al.: Higher remission and maintenance of response rates with subcutaneously monthly certolizumab pegol in patients with recent onset Crohn's disease: data from PRECiSE2. Am J Gastroenterol 2006, 101:S434-S435.
20. Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, [In press].
21. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al.: Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
22. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
23. Sandborn WJ, Kamm MA, Lichtenstein GR, et al.: MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007, 26:205-215.
24. Hellers G, Cortot A, Jewell D, et al.: Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999, 116:294-300.
25. Modigliani R, Mary JY, Simon JF, et al.: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
26. D'Haens G, Geboes K, Rutgeerts P: Endoscopic and histologic healing of Crohn's (ileo-)colitis with azathioprine. Gastrointest Endosc 1999, 50:667-671.
27. Panaccione R: The use of methotrexate is associated with mucosal healing in Crohn's disease. Gastroenterology 2005, 128(Suppl):A49.
28. Ardizzone S, Maconi G, Russo A, et al.: Randomised controlled trial of azathioprine and 5-aminosaticylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
29. Present DH, Korelitz BI, Wisch N, et al.: Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N EnglJ Med 1980, 302:981-987.
30. Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127: 723-729.
31. D'Haens G, van Deventer S, Van Hogzand R, et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
32. Rutgeerts P, Diamond RH, Bala M, et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442, quiz 64.
33. Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
34. Mottonen TT: Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988, 47:648-653.
35. Egsmose C, Lund B, Borg G, et al.: Patients with rheumatoid arthritis benefit from early second line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995, 22:2208-2213.
36. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al.: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146:406-415.
37. Lionetti P, Bronzini F, Salvestrini C, et al.: Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18:425-431.
38. Hyams JS, Crandall W, Kugathasan S, et al.: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873.
39. Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
40. Schreiber S, Reinisch W, Colombel JF, et al.: Early Crohn's disease shows high levels of remission to therapy with adalimumab. Sub-analysis of CHARM. Gastroenterology 2007, 132:A147.
41. Schreiber S, Targan S: Efficacy of natalizumab in Crohn's patients with disease duration less than 3 years. Gastroenterology 2007, 132:A509.
42. Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
43. Hommes DW, Baert F, van Assche G, et al.: A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): top-down versus step-up strategies. Gastroenterology 2006, 130:A108-A109.
44. D'Haens G, Hommes DW, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than the classic step-up therapy in newly diagnosed Crohn's. Gastroenterology 2006, 130:A110.
45. Crum NF, Lederman ER, Wallace MR: Infections associated with tumor necrosis factor-alpha antagonists. Medicine 2005, 84:291-302.
46. Hansen RA, Gartlehner G, Powell GE, Sandler RS: Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007, 5:729-735e1.
47. Mackey AC, Green L, Liang LC, et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. Journal Pediatr Gastroenterol Nutr 2007, 44:265-267.
48. Yousry TA, Major EO, Ryschkewitsch C, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
49. Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
50. Beaugerie L, Seksik P, Nion-Larmurier I, et al.: Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.